Rare disease drug development is a long and costly process. Though estimates vary widely, it can take as much as $1.5 billion and 15 years to bring a new drug from discovery to the marketplace. Today, a new world of open source biology and crowd funding give many patient advocates the ability to enter the drug development world. Could a patient’s family, frustrated by the lack of industry interest in a disease, go out and fund research and drug development that could put treatments and cures in reach?
The first step is to understand the process of drug development and the points at which you can get involved to accelerate the process. There are many entry points within drug development where patient advocates can and should take an active role, all the way through the FDA approval process.
- Scott Johnson, CEO, President and Founder of the Myelin Repair Foundation
- Dr. Kenneth Kaitin, Director, Tufts Center for the Study of Drug Development
- Dr. Bruce Bloom, President and Chief Science Officer of Cures Within Reach
Moderator: Daniel Levine, Managing Director of Publications at Burrill & Company